医学
LMNA公司
心脏病学
内科学
射血分数
心力衰竭
心室
肌营养不良
心脏再同步化治疗
厄贝沙坦
血压
拉明
精神科
核心
作者
Taras V Chendey,Mykola Rishko,Victoria I Chendey
出处
期刊:Wiadomości lekarskie (Warsaw Poland)
[ALUNA]
日期:2023-01-01
卷期号:76 (11): 2531-2534
标识
DOI:10.36740/wlek202311130
摘要
A 25-year-old male with known EDMD was referred for the cardiology consultation due to symptoms of heart failure. Echocardiography showed decrease left ventricular ejection fraction (LVEF) and therapy with ramipril, torsemide and rivaroxaban was initiated. Despite initial improvement, the patient later developed presyncope, bradycardia, irregular heartbeat and worsening of dyspnea. Therefore, implantation of resynchronization pacemaker with the function of implantable cardioverter-defibrillator (CRT-D/P) was performed. Ramipril was substituted by sacubitril/valsartan, and mineralocorticoid receptor antagonist and beta-blocker were initiated. Genetic testing found AD mutation in lamin A/C gene LMNA c.746G>A, p.(Arg249Gln). Upon follow-up, the patient demonstrated resolution of dyspnea and reverse remodeling of the left ventricle with complete restoration of the LVEF.
科研通智能强力驱动
Strongly Powered by AbleSci AI